ISB News

For the first time in the U.S.: Join ISB for BIO-FICTION

Join us on Thursday, May 7
at Institute for Systems Biology 
in South Lake Union

Doors open at 4:30pm. Screening begins at 5:00pm, followed by a panel discussion.

BIO·FICTION explores the emerging field of synthetic biology from different disciplinary angles including science and engineering, social science, cultural studies, amateur biology, film making, art and design. The original program had presentations, panel discussions, do-it-yourself biology demos, performances, art works and, of course, film screenings. It featured short films on any aspect of synthetic biology, including documentary films, animation, and science fiction. BIO·FICTION was created by Markus Schmidt and Camillo Meinhart and was held in Vienna in 2011 and again in 2014. Institute for Systems Biology (ISB) is the first organization to share the event in the United States.

The screening is free and happening in conjunction to South Lake Union Art Walk. Reserve your spot!

RSVP

 

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.